Hypocalcemia (low blood calcium level) is total serum calcium levels below 8.5 mg/dL. Laboratories may vary slightly on ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the readout ...

LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...

Eneboparatide is an investigational parathyroid hormone (PTH) receptor 1 agonist. By binding to a specific conformation of the PTH receptor 1, eneboparatide is expected to restore PTH function and ...

Find insights on AstraZeneca, Incyte and more in the latest Market Talks from the health-care sector.

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...

High-level results from the CALYPSO Phase III trial showed that eneboparatide, AZP-3601, an investigational parathyroid hormone receptor 1 ...

Clinicians should monitor patients with stones, even if they are asymptomatic, to slow kidney function decline, investigators suggest. Even asymptomatic kidney stones may spur kidney function decline ...